Pfizer Will Market Monogram Biosciences CCR5 Test to Help Identify Responders to New HIV Drug

Monogram s phenotypic CCR5 assay has the opportunity to become the first such test on the market, with the potential to be useful in predicting patient response to other drugs of the same class. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.